Day One Biopharmaceuticals (NASDAQ:DAWN – Get Rating) had its price objective raised by HC Wainwright from $35.00 to $45.00 in a research report sent to investors on Monday morning, The Fly reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Day One Biopharmaceuticals' Q4 2023 earnings at ($0.63) EPS, FY2023 earnings at ($2.56) EPS, FY2024 earnings at ($2.38) EPS, FY2025 earnings at ($1.49) EPS, FY2026 earnings at $0.05 EPS and FY2027 earnings at $1.67 EPS.

Other equities research analysts have also issued research reports about the company. The Goldman Sachs Group initiated coverage on Day One Biopharmaceuticals in a research note on Monday, December 5th. They set a buy rating and a $45.00 price objective for the company. Needham & Company LLC initiated coverage on Day One Biopharmaceuticals in a research note on Wednesday, December 14th. They set a buy rating and a $40.00 price objective for the company. Bank of America initiated coverage on Day One Biopharmaceuticals in a research note on Thursday, December 1st. They set a buy rating and a $34.00 price objective for the company. Finally, Piper Sandler raised their price objective on Day One Biopharmaceuticals from $40.00 to $45.00 and gave the company an overweight rating in a research note on Sunday. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of Buy and a consensus target price of $43.50.

Day One Biopharmaceuticals Trading Up 0.7 %

Shares of NASDAQ:DAWN opened at $22.98 on Monday. Day One Biopharmaceuticals has a one year low of $5.44 and a one year high of $28.35. The business's 50-day simple moving average is $20.80 and its 200 day simple moving average is $20.83.

Insider Transactions at Day One Biopharmaceuticals

In other news, CFO Charles N. York II sold 10,000 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, November 1st. The stock was sold at an average price of $20.03, for a total value of $200,300.00. Following the completion of the transaction, the chief financial officer now owns 294,401 shares in the company, valued at approximately $5,896,852.03. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, Director Julie Papanek Grant sold 5,000 shares of the business's stock in a transaction that occurred on Tuesday, November 1st. The stock was sold at an average price of $20.04, for a total transaction of $100,200.00. Following the completion of the transaction, the director now owns 424,358 shares in the company, valued at approximately $8,504,134.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Charles N. York II sold 10,000 shares of the business's stock in a transaction that occurred on Tuesday, November 1st. The shares were sold at an average price of $20.03, for a total value of $200,300.00. Following the transaction, the chief financial officer now owns 294,401 shares of the company's stock, valued at approximately $5,896,852.03. The disclosure for this sale can be found here. In the last quarter, insiders sold 129,178 shares of company stock worth $2,686,787. 8.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Amalgamated Bank bought a new stake in Day One Biopharmaceuticals during the 1st quarter valued at $30,000. ACG Wealth bought a new stake in Day One Biopharmaceuticals during the 2nd quarter valued at $32,000. TCI Wealth Advisors Inc. bought a new stake in Day One Biopharmaceuticals during the 2nd quarter valued at $35,000. Quantbot Technologies LP bought a new stake in Day One Biopharmaceuticals during the 2nd quarter valued at $51,000. Finally, UBS Group AG bought a new stake in Day One Biopharmaceuticals during the 2nd quarter valued at $69,000. Institutional investors and hedge funds own 86.08% of the company's stock.

About Day One Biopharmaceuticals

(Get Rating)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.

Recommended Stories

• Get a free copy of the StockNews.com research report on Day One Biopharmaceuticals (DAWN)
• Bloom Energy Powers Up After an Upgrade, is it Worth the Risk?
• Why Hershey Is a Sweet Recession Stock
• Will Amazon Stock Be Delivering for Investors in 2023?
• The Analysts Shift Trucking Sentiment Back into Forward
• The Institutions Book A Flight With Boeing

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.